anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a zinc(II) complex containing a natural material and its derivative and a zinc source as main components and useful as a food and medicine having action to increase hemocyte deformability, i.e. blood flow promoting action.  <P>SOLUTION: The invention relates to a pharmaceutical preparation and a preventive composed of a zinc(II) organic complex containing amino acids, picolinic acids, niacins, vitamins, carboxylic acids, maltols, amines, their derivatives and a compound composed of an organic substance having pyridine ring and thiazolidine ring, etc., as a ligand, and having hemocyte deformability increasing effect, i.e. blood flow promoting action. The invention further relates to a food such as a specified health food, a health (functional) food and a nutrient (functional) food containing the complex.  <P>COPYRIGHT: (C)2004,JPO
An orthodontic bone screw and its operational guide. The orthodontic bone screw is consisted of a main-neck and a sub-neck. An elastic element can be attached to either part of it. The bone screw also provides a chamfering to prevent abrasion. Moreover, the bone screw contains a hole through which an elastic element can be connected with the bone screw. The hole defines a block space which restricts the elastic element's rotation when inserted. In addition, the bone screw's threads reinforce the locking capacity in the jawbone. Furthermore, the threads offer a stop plane for enhanced stability.
Coronary artery disease has a high mortality rate and is a striking public health concern, affecting a substantial portion of the global population. On the early onset of myocardial ischemia, thrombolytic therapy and coronary revascularization could promptly restore the bloodstream and nutrient supply to the ischemic tissue, efficiently preserving less severely injured myocardium. However, the abrupt re-establishment of blood flow triggers the significant discharge of previously accumulated oxidative substances and inflammatory cytokines, leading to further harm referred to as ischemia/reperfusion (I/R) injury. Diabetes significantly raises the vulnerability of the heart to I/R injury due to disrupted glucose and lipid processing, impaired insulin sensitivity and metabolic signaling, and increased inflammatory responses. Numerous studies have indicated that adipokines are crucial in the etiology and pathogenesis of obesity, diabetes, hyperlipidemia, hypertension, and coronary artery disease. Adipokines such as adiponectin, adipsin, visfatin, chemerin, omentin, and apelin, which possess protective properties against inflammatory activity and insulin resistance, have been shown to confer myocardial protection in conditions such as atherosclerosis, myocardial hypertrophy, myocardial I/R injury, and diabetic complications. On the other hand, adipokines such as leptin and resistin, known for their pro-inflammatory characteristics, have been linked to elevated cardiac lipid deposition, insulin resistance, and fibrosis. Meteorin-like (metrnl) exhibits opposite effects in various pathological conditions. However, the data on adipokines in myocardial I/R, especially in diabetes, is still incomplete and controversial. This review focuses on recent research regarding the categorization and function of adipokines in the heart muscle, and the identification of different signaling pathways involved in myocardial I/R injury under diabetic conditions, aiming to facilitate the exploration of therapeutic strategies against myocardial I/R injury in diabetes.
<P>PROBLEM TO BE SOLVED: To provide a pharmaceutical given by searching a component having action of inducing expression or accelerating production of antibacterial peptide defensin, containing the component as an active ingredient, and therefore having the action of inducing the expression or accelerating the production of the antibacterial peptide defensin, and to provide food and drink having the action.  <P>SOLUTION: The agent for inducing the expression or accelerating the production of the antibacterial peptide in a digestive tract tissue contains a mannan-containing component derived from yeast as the active ingredient. The mannan-containing component preferably has a mannose content of ≥60 mass%. The agent is used for inducing the expression or accelerating the production of α-defensin or β-defensin as the antibacterial peptide. The pharmaceutical and the food and drink contain the agent, respectively.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Systems and methods for determining indicators of risk of patients to adverse healthcare events and presentation of the same are disclosed. According to an aspect, a method includes receiving, from a database, data associated with a plurality of individuals. The method also includes correlating the data to an adverse healthcare event for one or more of the individuals. Further, the method includes generating a model that relates the data to the adverse healthcare event based on the correlation of the data to the adverse healthcare event. The method also includes applying the model to data of another individual to generate an indicator of risk of the other individual to the adverse healthcare event. Further, the method includes presenting the indicator of risk via a user interface.
Methods for treating the animal central nervous system for the effects of traumatic brain injury. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient suffering from traumatic brain injury. The effective amount of DFO is delivered directly to the patient's central nervous system for treating the traumatic brain injury.
A mineral material for preventing demineralization of enamel, and an application thereof. The mineral material comprises a film forming protein (lysozyme, bovine serum albumin, insulin, and α-lactalbumin, etc.), amelogenin peptide, soluble phosphate, tri(2-carboxyethyl)phosphine hydrochloride, and a pH regulator. Mouthwash can be prepared by mixing the mineral material and an HEPES buffer solution diluted by ultrapure water, and toothpaste can be prepared by using a toothpaste auxiliary material, and other products for preventing demineralization of enamel are further prepared. The film forming protein molecules and tri(2-carboxyethyl)phosphine hydrochloride undergo phase transformation to form an amelogenin peptide-cladded biological protein two-dimensional nano film on the surface of enamel. The thin film is able to be quickly attached to the surface of the enamel, and biological mineralization is caused in saliva by mediation of the thin film, so as to grow new hydroxyapatite having high orientation on the surface of the enamel. The remineralized is similar to natural enamel, so that enamel demineralized by acid etching is repaired and tooth decay is prevented.
Treatment with SKYCLARYS can cause an elevation in hepatic transaminases (ALT and AST). In Study 1 [see Clinical Studies (14)], the incidence of elevations of ALT or AST above 5 times and 3 times the upper limit of normal (ULN) was 16% and 31%, respectively, in patients treated with SKYCLARYS. There were no cases of concomitant elevation of transaminases and total bilirubin observed in Study 1. Maximum increases in ALT and AST occurred within 12 weeks after starting SKYCLARYS. Increases in serum aminotransferases were generally asymptomatic and reversible following discontinuation of SKYCLARYS. Patients with clinically significant liver disease were excluded from Study 1. 

Monitor ALT, AST, and total bilirubin prior to initiation of SKYCLARYS, every month for the first 3 months of treatment, and periodically thereafter. If transaminases increase to levels greater than 5 times the ULN, or greater than 3 times the ULN with evidence of liver dysfunction (e.g., elevated bilirubin), immediately discontinue SKYCLARYS and repeat liver function tests as soon as possible. If transaminase levels stabilize or resolve, SKYCLARYS may be reinitiated with an appropriate increased frequency of monitoring of liver function [see Adverse Reactions (6.1) and Use in Specific Populations (8.6)].
On the morning of challenge, subjects will drink 120 mL of bicarbonate buffer. Approximately 1 minute later, subjects will drink a solution of virulent H10407 bacteria suspended in the remaining 30 mL of bicarbonate buffer (2 x 10P7P cfu).
Patients with Impaired Renal Function

The pharmacokinetics of emtricitabine are altered in patients with renal impairment [See Warnings and Precautions (5.4)]. In adult patients with creatinine clearance <50 mL/min or with end-stage renal disease (ESRD) requiring dialysis, Cmax and AUC of emtricitabine were increased due to a reduction in renal clearance (Table 7). It is recommended that the dosing interval for EMTRIVA be modified in adult patients with creatinine clearance <50 mL/min or in adult patients with ESRD who require dialysis [See Dosage and Administration (2.5)]. The effects of renal impairment on emtricitabine pharmacokinetics in pediatric patients are not known.

Hemodialysis: Hemodialysis treatment removes approximately 30% of the emtricitabine dose over a 3-hour dialysis period starting within 1.5 hours of emtricitabine dosing (blood flow rate of 400 mL/min and a dialysate flow rate of 600 mL/min). It is not known whether emtricitabine can be removed by peritoneal dialysis.
The invention belongs to the technical field of veterinary drug production, and provides PCV2-SVA bigeminal seedlings. The vaccine takes PCV2 Cap protein and SVA VP2 protein which remove nuclear localization signals as antigens. The invention efficiently expresses the soluble PCV2 Cap protein and SVA VP2 protein through a rod-shaped system. Due to the immunological synergy, PCV2-SVA bivalent vaccine prepared based on recombinant protein can stimulate the generation of higher level humoral immunity and cellular immunity compared with commercial vaccine or inactivated vaccine. The virus-attack protection test after immunization shows that the bivalent vaccine can effectively reduce the virus content in viremia and viscera. The bivalent genetic engineering vaccine against PCV2 and SVA developed based on the invention has commercial development prospect.
Circulating miRNA has recently emerged as important biomolecules with potential clinical values as diagnostic markers for several diseases. However, to be used as such, it is critical to accurately quantify miRNAs in the clinic. Yet, preanalytical factors that can affect an error-free quantification of these miRNAs have not been explored. This study aimed at investigating several of these preanalytical factors that may affect the accurate quantification of miRNA-451a, miRNA-423-5p and miRNA-199a-3p in human blood samples. We initially evaluated levels of these three miRNAs in red blood cells (RBCs), white blood cells (WBCs), platelets, and plasma by droplet digital PCR (ddPCR). Next, we monitored miRNA levels in whole blood or platelet rich plasma (PRP) stored at different temperatures for different time periods by ddPCR. We also investigated the effects of hemolysis on miRNA concentrations in platelet-free plasma (PFP). Our results demonstrate that more than 97% of miRNA-451a and miRNA-423-5p in the blood are localized in RBCs, with only trace amounts present in WBCs, platelets, and plasma. Highest amount of the miRNA-199a-3p is present in platelets. Hemolysis had a significant impact on both miRNA-451a and miRNA-423-5p concentrations in plasma, however miRNA-199a levels remain unaffected. Importantly, PRP stored at room temperature (RT) or 4°C showed a statistically significant decrease in miRNA-451a levels, while the other two miRNAs were increased, at days 1, 2, 3 and 7. PFP at RT caused statistically significant steady decline in miRNA-451a and miRNA-423-5p, observed at 12, 24, 36, 48 and 72 hours. Levels of the miRNA-199a-3p in PFP was stable during first 72 hours at RT. PFP stored at -20°C for 7 days showed declining stability of miRNA-451a over time. However, at -80°C miRNA-451a levels were stable up to 7 days. Together, our data indicate that hemolysis and blood storage at RT, 4°C and -20°C may have significant negative effects on the accuracy of circulating miRNA-451a and miRNA-423-5p quantification.
Background: Breast cancer-related lymphedema (BCRL) is the most prevalent comorbidity that occurs following breast cancer treatments and has negative impact on the patients' quality of life (QoL). The Lymphedema Functioning, Disability, and Health Questionnaire for Upper Limb Lymphedema (Lymph-ICF-UL) is a valid and reliable instrument in assessing the QoL of patients with BCRL. However, the Bahasa Malaysia (BM) version is not available yet. This study aimed to translate the Lymph-ICF-UL into BM and to evaluate its validity and reliability. Methods and Results: A forward-backward translation was performed based on Sousa's guideline, and then, the face, content, construct validity, internal consistency, and test-retest reliability were tested. Face validity was assessed by five patients, and content validity was evaluated by six experts. Then, construct validity and internal validity were assessed in 107 patients. Finally, test-retest reliability was analyzed in 21 patients. Two items were eliminated following suggestions from the patients and experts. All patients found the scoring system and items clear and relevant. The results showed sufficient content validity index and modified kappa statistics value. Confirmatory factor analysis showed acceptable fit indices. Cronbach's alpha values ranged from 0.67 to 0.95, intraclass correlation coefficient ranged from 0.88 to 0.99, standard error measurement was 2.29-6.15, and the Bland-Altman plot showed an agreement between two test occasions. Conclusion: These results suggested that the Lymph-ICF-UL BM has good validity and reliability in evaluating the QoL of patients with BCRL in Malaysia.
Patients receive androgen ablation as in arm I. Patients receive GVAX prostate cancer vaccine (CG1940 and CG8711) intradermally (ID) on day 1. Beginning on day 1 of week 3, patients receive booster doses of CG1940 and CG8711 ID every 2 weeks for 24 weeks.
PURPOSE: A pharmaceutical composition and a food composition containing a tuna eye extract as an active ingredient for preventing or treating arthritis is provided to effectively suppress autoimmune diseases and inflammation which are developed in joint without side effects by inducing immunotolerance and to prevent and treat arthritis. CONSTITUTION: A pharmaceutical composition for preventing and treating arthritis contains a tuna eye crushed material or extract as an active ingredient. The composition induces immunotolerance which occurs in gut associated lymphoid tissue (GALT). The composition additionally contains glucosamine, chondroitin, or a combination thereof. A food composition for treating arthritis contains the tuna eye crushed material or extract as an active ingredient. [Reference numerals] (AA) Score; (BB) Comparative example 1-3; (CC) Comparative example 1-2; (DD) Comparative example 1-1; (EE) Example 1-3; (FF) Example 1-2; (GG) Example 1-1; (HH) Negative control group; (II) Number of elapse days
Meropenem administered intravenously once daily over 6 hours plus amoxicillin/clavulanate 2 x 1000/62.5 mg once daily orally plus bedaquiline 400 mg orally once daily. All study treatments will be administered for 14 consecutive days.
Participants randomized to the waitlist control (or delayed treatment) condition will receive written and verbal feedback after the baseline assessment visit. These families will participate in follow-up visits at 3 months, 6 months, and 12 months after the baseline visit. They will receive the same treatment (PCIT) after the 6-month assessment.
BACKGROUND: Parents may seek out health information online when their adolescent has nonspecific back pain to better understand treatment options. Such information directed towards consumers has not been previously analysed.
METHODS: A descriptive cross-sectional content analysis was performed to describe the treatments recommended on consumer websites for nonspecific back pain in adolescents. The credibility and readability of the websites were also assessed. Systematic Google searches were completed in five countries, and relevant content from eligible web pages was analysed. An a priori codebook with 34 treatment-related codes was developed. Nine additional codes were inductively created during analysis. Credibility was assessed using the JAMA benchmark. Readability was assessed via the Flesch Kincaid Grade Level.
RESULTS: Of 245 web pages, 48 were deemed eligible and analysed. Of 43 treatment codes, 37 were present in at least one web page. The five most frequently identified codes were See the doctor/get a diagnosis (found on 85% of web pages), Ergonomics/posture/biomechanics (52%), Reassurance (48%), Physiotherapy (48%) and Non-prescription pharmaceuticals/supplements (46%). Only 21% of the web pages met all four JAMA benchmark criteria, and 15% cited at least one recent or high-quality source. The median Flesch Kincaid Grade Level score was 9.0 (range 3.5-12.9).
CONCLUSIONS: Parents of adolescents with nonspecific back pain may find that treatment recommendations published online are numerous and varied, with visits to the doctor encouraged. The credibility scores of these web pages are generally low, while the median reading level may be too high for the general population.
SIGNIFICANCE STATEMENT: This analysis reveals that public-facing websites with recommendations for treating adolescent nonspecific back pain do not cite the most recent, high-quality research. Although web pages correctly encourage physical activity and exercise over surgery and prescription medications, they do not reflect the psychologically informed or interdisciplinary care emphasized in recently published treatment recommendations. Clinicians must be aware that caregivers of their adolescent patients with nonspecific back pain may be exposed to online messages that encourage them to keep seeking a diagnosis.
PCT No. PCT/SE92/00631 Sec. 371 Date May 16, 1994 Sec. 102(e) Date May 16, 1994 PCT Filed Sep. 14, 1992 PCT Pub. No. WO93/09820 PCT Pub. Date May 27, 1993.System employing a sterile medical solution containing glucose or glucose polymers, for example nutritional solutions or solutions for peritoneal dialysis, whereby the majority of the solution is packed in a first package, while the glucose or the glucose polymers are separately packed in a second package, whereafter the two packages are heat sterilized. The content of the glucose or glucose polymers in the second package is maintained above 10% by weight, preferably above 20% by weight and most preferably in the order of 40% by weight in order to reduce or totally eliminate the breakdown of glucose. The medical solution after sterilization, mixing and diluting to 1.5% glucose content has an absorbency caused by breakdown products from glucose at 228 nm less than 0.35 and preferably in the order of 0.20 or lower. The medical solution is also defined in that after sterilization, mixing and dilution to 1.5% glucose content it has an ICG-value caused by breakdown products from glucose less than 50% and preferably less than 30%.
We propose to measure the response of symptoms and cognition in people schizophrenia given acamprosate or placebo. We hypothesize that symptoms and cognition will improve following two weeks of acamprosate. We will also use proton magnetic resonance spectroscopy (MRS) to examine the effect of acamprosate on glutamate \& glutamine (Glu\&Gln) brain levels in people with schizophrenia. We hypothesize that Glu\&Gln concentrations in people with chronic schizophrenia will increase following two weeks of treatment with acamprosate.

The proposed study will consist of 50 individuals with chronic schizophrenia/schizoaffective disorder, 18-55 years old, from in/outpatient programs at the Maryland Psychiatric Research Center (MPRC). The dose of acamprosate will follow manufacturer recommendations with two 333mg tablets given three times per day. MRS will be acquired from areas involved in schizophrenia \[dorsolateral-prefrontal cortex (DLPFC) and anterior cingulate cortex (ACC)\] at baseline and week two. Symptom ratings and cognitive testing will occur at baseline and be repeated at week two.
BRAFV600E mutation is a driver mutation in the serrated pathway to colorectal cancers. BRAFV600E drives tumorigenesis through constitutive downstream extracellular signal-regulated kinase (ERK) activation, but high-intensity ERK activation can also trigger tumor suppression. Whether and how oncogenic ERK signaling can be intrinsically adjusted to a 'just-right' level optimal for tumorigenesis remains undetermined. In this study, we found that FAK (Focal adhesion kinase) expression was reduced in BRAFV600E-mutant adenomas/polyps in mice and patients. In Vil1-Cre;BRAFLSL-V600E/+;Ptk2fl/fl mice, Fak deletion maximized BRAFV600E's oncogenic activity and increased cecal tumor incidence to 100%. Mechanistically, our results showed that Fak loss, without jeopardizing BRAFV600E-induced ERK pathway transcriptional output, reduced EGFR (epidermal growth factor receptor)-dependent ERK phosphorylation. Reduction in ERK phosphorylation increased the level of Lgr4, promoting intestinal stemness and cecal tumor formation. Our findings show that a 'just-right' ERK signaling optimal for BRAFV600E-induced cecal tumor formation can be achieved via Fak loss-mediated downregulation of ERK phosphorylation.